search
Back to results

A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99) (ACCURATE)

Primary Purpose

Renal Tumor, Renal Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Robot assisted partial nephrectomy with 3D image guidance
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Tumor focused on measuring image guidance, augmented reality, robotics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients over 18 years
  • Indication of RAPN for suspicious renal tumor
  • Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) >7)
  • Da Vinci® surgical system available for the surgery
  • Patient affiliated to the French social security system or an equivalent system
  • Signed informed consent form UroCCR and ACCURATE

Exclusion Criteria:

  • Medical contraindication to RAPN
  • Renal insufficiency forbidding iodine injection
  • Patient with allergy to iodinated contrast products
  • Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    conventional group

    3D IGRAPN GROUP

    Arm Description

    Robot-Assisted Partial Nephrectomy without 3D navigation

    Robot-Assisted Partial Nephrectomy with 3D navigation

    Outcomes

    Primary Outcome Measures

    TRIFECTA score
    evaluating peri-operative outcome complications as well as oncological safety and long-term renal function preservation.

    Secondary Outcome Measures

    Recurrence free survival
    Recurrence-free survival and Overall survival
    Overall survival
    Overall Survival
    Number of Conversion to radical nephrectomy
    Need to convert to radical nephrectomy for intra-operative reasons
    rate of Off clamp or superselective ischemia
    use of techniques without renal artery clamping
    Amount of parenchyma preserved (according to CT scan)
    Preservation of safe kidney
    Blood loss
    Blood loss
    NASA TLX
    Ergonomy score (questionnaire completed at the end of the procedure by the surgeon)
    Warm ischemia time
    Warm ischemia time
    Medico-economic evaluation
    ncremental cost-utility ratio (ICUR) expressed as the extra cost per a QALY gained by the 3D-IGRAPN strategy compared to standard RAPN.

    Full Information

    First Posted
    October 5, 2022
    Last Updated
    October 6, 2022
    Sponsor
    University Hospital, Grenoble
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05572216
    Brief Title
    A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
    Acronym
    ACCURATE
    Official Title
    A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 2022 (Anticipated)
    Primary Completion Date
    December 2022 (Anticipated)
    Study Completion Date
    November 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Grenoble

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to evaluate peri and post-operative outcomes as well as long-term survival of 3D IGRAPN compared to conventional Robot-Assisted Partial Nephrectomy (RAPN) for moderate and highly complex renal tumors. The main questions aim to answer: peri-operative complications oncological safety long term renal function Participants will be asked to do undergo 3D-IGRAPN. Researchers will compare 3D-IGRAPN to RAPN to see if peri-operative outcomes are better in the experimental group.
    Detailed Description
    Robot-assisted partial nephrectomy (RAPN) is the standard treatment for localized kidney tumors. New 3D modeling and reconstruction technologies have enabled the development of real time imageguided surgery using virtual reality (VR). In view of advances in artificial intelligence and surface recognition based on deep-learning, augmented reality (AR) by merging a 3D reconstructed virtual image onto the real per-operative view represents the next step in image-guided surgery. 3D IG-RAPN using Synapse 3D (Fujifilm) and DaVinci Tile-Pro display (Intuitive Surgical) vs conventional RAPN without 3D navigation in 12 high-volume urological centers from the UroCCR Network. Outcoume : Primary endpoint is a composite validated score (TRIFECTA) evaluating peri-operative complications as well as oncological safety and long-term renal function preservation. Secondary endpoints assess long-term survival, ergonomics and surgeon satisfaction. A medico-economic evaluation will be performed. Methodology: ACCURATE is a nation-wide, single-blind, multicentric, prospective randomized controlled trial enrolling 694 patients with a single complex renal mass, defined as RENAL NS≥7. Randomization (1:1) between the experimental and the conventional group will take place on day of inclusion and will be stratified by center.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Renal Tumor, Renal Cancer
    Keywords
    image guidance, augmented reality, robotics

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    ACCURATE is a nation-wide, single-blind, multicentric, prospective randomized controlled trial enrolling patients with a single complex renal mass, defined as RENAL NS≥7. Randomization (1:1) between the experimental and the conventional group will take place on day of inclusion and will be stratified by center.
    Masking
    Participant
    Masking Description
    single blind
    Allocation
    Randomized
    Enrollment
    694 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    conventional group
    Arm Type
    No Intervention
    Arm Description
    Robot-Assisted Partial Nephrectomy without 3D navigation
    Arm Title
    3D IGRAPN GROUP
    Arm Type
    Experimental
    Arm Description
    Robot-Assisted Partial Nephrectomy with 3D navigation
    Intervention Type
    Procedure
    Intervention Name(s)
    Robot assisted partial nephrectomy with 3D image guidance
    Other Intervention Name(s)
    without 3D image guidance
    Intervention Description
    patient have a partial nephrectomy for renal complex tumor
    Primary Outcome Measure Information:
    Title
    TRIFECTA score
    Description
    evaluating peri-operative outcome complications as well as oncological safety and long-term renal function preservation.
    Time Frame
    1 month
    Secondary Outcome Measure Information:
    Title
    Recurrence free survival
    Description
    Recurrence-free survival and Overall survival
    Time Frame
    2 and 5 years
    Title
    Overall survival
    Description
    Overall Survival
    Time Frame
    2 and 5 years
    Title
    Number of Conversion to radical nephrectomy
    Description
    Need to convert to radical nephrectomy for intra-operative reasons
    Time Frame
    Intraopertively
    Title
    rate of Off clamp or superselective ischemia
    Description
    use of techniques without renal artery clamping
    Time Frame
    Intraoperatively
    Title
    Amount of parenchyma preserved (according to CT scan)
    Description
    Preservation of safe kidney
    Time Frame
    Month 6
    Title
    Blood loss
    Description
    Blood loss
    Time Frame
    Intra-operatively
    Title
    NASA TLX
    Description
    Ergonomy score (questionnaire completed at the end of the procedure by the surgeon)
    Time Frame
    at the end of the surgery
    Title
    Warm ischemia time
    Description
    Warm ischemia time
    Time Frame
    Intra-operatively
    Title
    Medico-economic evaluation
    Description
    ncremental cost-utility ratio (ICUR) expressed as the extra cost per a QALY gained by the 3D-IGRAPN strategy compared to standard RAPN.
    Time Frame
    Month 1 and 6

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients over 18 years Indication of RAPN for suspicious renal tumor Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) >7) Da Vinci® surgical system available for the surgery Patient affiliated to the French social security system or an equivalent system Signed informed consent form UroCCR and ACCURATE Exclusion Criteria: Medical contraindication to RAPN Renal insufficiency forbidding iodine injection Patient with allergy to iodinated contrast products Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jean-Alexandre LONG, Pr
    Phone
    0476767642
    Ext
    +33
    Email
    jalong@chu-grenoble.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    ASSILAH BOUZIT
    Phone
    0476767971
    Ext
    +33
    Email
    abouzit@chu-grenoble.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jean-Alexandre LONG, Pr
    Organizational Affiliation
    University Hospital, Grenoble
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    33811291
    Citation
    Michiels C, Khene ZE, Prudhomme T, Boulenger de Hauteclocque A, Cornelis FH, Percot M, Simeon H, Dupitout L, Bensadoun H, Capon G, Alezra E, Estrade V, Bladou F, Robert G, Ferriere JM, Grenier N, Doumerc N, Bensalah K, Bernhard JC. 3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51). World J Urol. 2023 Feb;41(2):303-313. doi: 10.1007/s00345-021-03645-1. Epub 2021 Apr 2.
    Results Reference
    result
    PubMed Identifier
    31898992
    Citation
    Porpiglia F, Checcucci E, Amparore D, Piramide F, Volpi G, Granato S, Verri P, Manfredi M, Bellin A, Piazzolla P, Autorino R, Morra I, Fiori C, Mottrie A. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA >/=10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. 2020 Aug;78(2):229-238. doi: 10.1016/j.eururo.2019.11.024. Epub 2019 Dec 30.
    Results Reference
    result
    PubMed Identifier
    33931361
    Citation
    Long JA, Fiard G, Giai J, Teyssier Y, Fontanell A, Overs C, Poncet D, Descotes JL, Rambeaud JJ, Moreau-Gaudry A, Ittobane T, Bouzit A, Bosson JL, Lanchon C. Superselective Ischemia in Robotic Partial Nephrectomy Does Not Provide Better Long-term Renal Function than Renal Artery Clamping in a Randomized Controlled Trial (EMERALD): Should We Take the Risk? Eur Urol Focus. 2022 May;8(3):769-776. doi: 10.1016/j.euf.2021.04.009. Epub 2021 Apr 27.
    Results Reference
    result

    Learn more about this trial

    A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)

    We'll reach out to this number within 24 hrs